SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid reports of potential partnerships and investments from industry giants like Apple and TSMC, fueling speculation about its comeback in the semiconductor market. The community is buzzing with excitement, viewing these developments as a significant catalyst for growth and a validation of Intel's strategic pivot. Many anticipate further gains, driven by a combination of government support and renewed confidence in Intel's ability to compete in the AI and foundry space.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a 'free and fair' meme coin on the Bitcoin blockchain, with the community emphasizing its decentralized nature and organic growth. Discussions revolve around accumulating during dips and the potential for 'DOG-TOBER', while some debate its relationship with $CBLO. The community continues to highlight its strong fundamentals and unique position within the meme coin landscape.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as the community discusses its potential, drawing comparisons to previous meme coin success stories like $PEPE. Many users are highlighting its accessibility and ease of purchase through the Phantom Wallet on the Solana network.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQQF is trending as investors discuss its upcoming Nasdaq listing and potential impact on institutional investment. Community members are weighing the potential for share dilution following the uplisting, drawing parallels to a similar situation with DEFT. Optimistic investors believe the listing and government quantum requirements could drive significant growth, while others express concern over potential short-term volatility.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending due to a recently announced $1.1B convertible notes offering and a $3B AI hosting agreement with Fluidstack, backed by Google. While the offering initially sparked concerns about dilution, the community is weighing this against the potential for growth and expansion into HPC, with some seeing it as a strategic move. Bullish sentiment highlights Google's involvement and long-term prospects in the AI data center space.

Aventus Network

Aventus Network ($AVT.X) is trending as traders discuss its potential for a breakout, citing bullish chart setups and a low market cap. Community members are highlighting real-world partnerships and the possibility of Polkadot integration acting as a catalyst. Some users are pointing to its limited supply and Coinbase listing as factors that could drive significant price movement.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave ($CRWV) is trending amid discussions around its relationship with OpenAI and the broader AI infrastructure landscape, with community members debating the sustainability of its growth and comparing its valuation to peers. Some are pointing to insider selling and technical chart patterns, while others remain bullish, citing strong partnerships and potential for future growth in the AI sector. The stock's volatility and potential for both gains and losses are also being actively discussed.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending due to FDA approval for Palsonify, their oral acromegaly drug, sparking excitement among retail traders. The community is focused on the drug's potential impact and pricing, while anticipating a significant price movement. High institutional ownership and short interest are also fueling discussions about a potential short squeeze.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

Diginex ($DGNX) is trending as traders discuss its recent volatility and potential acquisitions, including Resulticks and Findings, which could transform it into a broad technology platform. Community members are also highlighting existing partnerships with major companies and significant investments from Abu Dhabi, suggesting long-term growth potential. Some are comparing $DGNX to other stocks with similar patterns, referencing possible high reward but high risk.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics ($AQST) is trending following CEO Barber's appearance on Mad Money, where he highlighted the blockbuster potential of their oral allergy film, Anaphylm. The community is buzzing about the positive interview and the future prospects of the company, with some speculating a buyout. Some are also discussing the competitive landscape, particularly in relation to $SPRY.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harmony Biosciences Holdings (HRMY) on Wednesday said that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance.Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. According to the company, the disease affects upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the U.K. The disease is more common in males than females, but there are no FDA-approved treatments for the disorder.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-provides-update-its-phase-3-reconnect-study">said</a> on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.Shares of HRMY traded 15% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_1_01_23_PM_png_17fb739829.webp" alt="HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Chief Medical Officer Kumar Budur stated that, although the study's findings did not meet the primary endpoint, they provide valuable insights into Fragile X syndrome. “We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community,” Budur said.The trial, which enrolled 215 patients with FXS aged 3 to under 30 years, aimed to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured synthetic cannabidiol.CEO Jeffrey M. Dayno stated that the company has additional candidates in its pipeline. “We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year,” he said.HRMY stock is down by 21% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Equity

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.


Actuate Therapeutics, Inc. (ACTU) announced on Monday that it has amended its application to the U.S. Food and Drug Administration (FDA) for its lead investigational drug Elraglusib in the treatment of pancreatic cancer.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/22/3153932/0/en/Actuate-Therapeutics-Provides-FDA-with-Updated-Clinical-Data-Package-to-Support-Planned-Regulatory-Interactions-with-FDA-and-EMA-Over-the-Coming-Months.html">stated</a> that it has amended the investigational new drug (IND) application with updated clinical data from its ongoing international mid-stage trial of the drug in the first-line treatment of metastatic pancreatic cancer. The study showed a statistically significant improvement in median overall survival with the combination arm of Elraglusib plus Gemcitabine/nab-paclitaxel (GnP) versus GnP alone, in addition to a 37% reduction in the risk of death.The data is intended to support planned regulatory submissions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) beginning later this year and continuing into early 2026, the company said. It also added that the data strengthens the case for Elraglusib as a back-bone therapy that can be combined with different regimens used to treat pancreatic cancer.The company is currently studying Elraglusib in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapies.<a href="https://stocktwits.com/symbol/ACTU">ACTU shares</a> traded 6% higher at the time of writing. On Stocktwits, retail sentiment around ACTU jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_11_15_37_AM_png_49248344ea.webp" alt="ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Actuate also stated that its recent $17.25 million public offering provides an extended runway into the second half of 2026.“We have already updated the clinical data package on file with the FDA, and during the remainder of this year and into the first quarter of 2026, we expect to gain clarity on Elraglusib’s regulatory path forward for the first-line treatment of metastatic PDAC,” said CEO Daniel Schmitt.ACTU stock is down by 11% this year but up by 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-rallies-after-piper-sandler-hikes-price-target/chDQA76R32Z">Tesla Stock Rallies After Piper Sandler Hikes Price Target – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer

Actuate on Monday also said that its recent $17.25 million public offering provides an extended runway into the second half of 2026. 

AMC Entertainment Holdings (AMC) shares jumped 5% during midday trading on Friday after the company announced it would play Taylor Swift’s “The Official Release Party Of A Showgirl” at all its 540 theatre locations and thousands of other movie theatre screens in North America, including Cinemark and Regal in the U.S.Swift’s 12th studio album, The Life of a Showgirl,&nbsp;is set to drop on October 3,&nbsp;and the movie will also be released on the same day.&nbsp;&nbsp;The movie will begin on Friday, October 3, and run through Sunday, October 5. AMC stated that it is approximately an 89-minute theatrical experience, which will include the exclusive world premiere of a music video from the album “The Fate of Ophelia” and behind-the-scenes footage from the music video shoot.Retail sentiment on <a href="https://stocktwits.com/symbol/AMC">AMC</a> remained in the ‘bullish’ territory, with chatter at ‘high’ levels, according ot data from Stocktwits.“The Official Release Party Of A Showgirl” will also play at Cineplex in Canada, Cinepolis and Cinemex in Mexico, beginning at 3 p.m. EDT. AMC will also bring it to theatres in 100 additional countries or more outside of the United States.AMC noted that this was the second collaboration between Swift and AMC Theatres Distribution, which in 2023 launched “The Eras Tour” concert film, which grossed more than $261 million at the global box office, making it the highest-grossing concert film of all time.Swift’s Eras Tour concert was held at various global cities for a span of nearly two years, with the last leg of the show wrapping up in December 2024.&nbsp;A bullish user on Stocktwits noted it has a “swifty effect.” This term has been in use since Swift’s Eras Tour concert, which helped boost consumer spending in economies and also resulted in an increase in traffic at Target stores during the release of copies of her new Eras Tour book and vinyl album.<stembedurl>https://stocktwits.com/Cojax0203/message/629316983</stembedurl>Shares of AMC have declined 37% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/brighthouse-financial-stock-jumps-26-after-this-potential-deal-repor/chD37BKR3TQ">Brighthouse Financial Stock Jumps 26% After This Potential Deal Report: More Details Inside</a>

Taylor Swift attends the 67th Annual GRAMMY Awards on February 02, 2025 in Los Angeles, California. (Photo by Matt Winkelmeyer/Getty Images for The Recording Academy)

AMC Entertainment Stock Is Rising Today And There’s A Taylor Swift Angle – Find Out More

Swift’s 12th studio album, The Life of a Showgirl, is set to drop on October 3, and the movie will also be released on the same day. 

Emergent BioSolutions Inc. (EBS) on Friday said that it has secured new purchase orders from an international government partner for a multiproduct supply agreement.The agreement is valued at $29 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-29-million-mcm-product-orders">said</a>. The order encompasses several product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. The company said that this is the second procurement made by the same government this year.Shares of the company jumped 3% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_11_37_08_AM_png_46c276596d.webp" alt="EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is “significantly undervalued,” while indicating that they see more than 100% upside.<stembedurl>https://stocktwits.com/NRG8/message/629302236</stembedurl>Another user expects the stock to hit $10 next week.<stembedurl>https://stocktwits.com/shoagh12/message/629291934</stembedurl>Emergent said it will receive about $26 million in 2025 under the agreement. This is in addition to more than $100 million in sales already generated for the company’s MCM portfolio outside the U.S. so far this year, it said.“Together with demand from the U.S. government, these international procurements reinforce the potential for our growth trajectory as part of Emergent’s multi-year transformation plan and highlights the strength of Emergent’s global footprint,” CEO Joe Papa said. The CEO also added that the company continues to see countries elevating their investment in defense preparedness.Emergent delivers solutions for health threats like Smallpox, Mpox, Botulism, Ebola, Anthrax, and Opioid overdose emergencies.Earlier this week, the company also announced that it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Tembexa oral suspension. At the start of the month, the company also announced that a contract modification had been executed for $56 million to supply ACAM2000, a live vaccinia virus vaccine approved by the FDA for use in preventing Smallpox and Mpox in individuals at high risk of infection, to the U.S. government.EBS stock is down 14% this year but up approximately 17% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-likely-preparing-22to24-per-share-bid-for-warner-bros-discovery/chD34ulR3Ta">Paramount Skydance Likely Preparing $22 To $24 Per Share Bid For Warner Bros. Discovery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’

The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.

Oklo Inc. (OKLO) shares jumped 18% in early trading on Friday, with the ticker trending at the top spot on Stocktwits following the signing of the Technology Prosperity Deal by U.S. President Donald Trump and Prime Minister Keir Starmer a day earlier.&nbsp;The stock has been on an uptrend in recent times, gaining over 87% in the last month. On Friday, the stock hit a record high of over $124. The retail user message count on Oklo increased by 540% in the last 24 hours, as of Friday morning, on Stocktwits.On Thursday, the White House said that this deal would help build commercial partnerships to accelerate the deployment of advanced nuclear reactors in both the U.S. and the U.K.&nbsp;Retail sentiment on <a href="https://stocktwits.com/symbol/OKLO">Oklo</a> jumped to ‘extremely bullish’ territory from ‘bullish’ a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.The White House stated that the Technology Prosperity Deal supports the U.S. Nuclear Regulatory Commission, the UK Office for Nuclear Regulation, and the UK Environment Agency (EA) in streamlining and accelerating licensing. This effort aims to target reactor design reviews within two years and site licensing within one year.This comes on the heels of the U.S. Department of Energy reportedly calling on uranium producers to accelerate resource development in an effort to bolster nuclear power expansion.A bullish user on Stocktwits highlighted that they have recorded a 900% return so far.<a href="https://stocktwits.com/i_like_the_stock_meow/message/629290849">https://stocktwits.com/i_like_the_stock_meow/message/629290849</a>Shares of Oklo have gained nearly 480% this year and increased by 1,366% over the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/this-stock-nearly-doubled-in-a-month-just-received-a-price-target-hike-by-roth-capital/chD33nxR3TI">This Stock Nearly Doubled In A Month, And It Just Received A Fresh Price Target Hike By Roth Capital – Find Out More</a>

Oklo Stock Continues To Be The Talk Of The Town After Gaining 87% In A Month – Here’s How Retail Investors Responded

On Thursday, U.S. President Donald Trump and Prime Minister Keir Starmer signed the Technology Prosperity Deal, which included the deployment of new nuclear power stations.

In this photo illustration, the Bloom Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Stock Nearly Doubled In A Month, And It Just Received A Fresh Price Target Hike By Roth Capital – Find Out More

Roth Capital stated that it views Bloom Energy’s current positioning as perhaps the most positive in the company’s history.

Intellia Therapeutics (NTLA) shares received a price target revision from H.C. Wainwright on Friday, with analyst Mitchell Kapoor raising the target to $30 from $25, following the stock's 30% rally on Thursday.The analyst kept a ‘Buy’ rating on the shares. The new price target implies an 86% upside to the stock’s closing price on Thursday.Intellia <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-completes-enrollment-global-phase-3-haelo">said</a> on Thursday that it has completed enrollment in the global late-stage HAELO study of Lonvoguran Ziclumeran (lonvo-z) for the treatment of hereditary angioedema. Data from the trial is expected to be released in the first half of 2026.According to Kapoor, the company’s nine-month enrollment completion in the pivotal late-stage trial shows the pull for a one-time therapy, as reported by TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:578/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_8_00_44_AM_png_583e54e2a8.webp" alt="NTLA's Sentiment Meter and Message Volume as of 8:00 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="64"><figcaption>NTLA's Sentiment Meter and Message Volume as of 8:00 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded positive on the stock in the wake of the upcoming data from the study.<stembedurl>https://stocktwits.com/AdiKrononaut/message/629242354</stembedurl>Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring, and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating, and life-threatening. It is estimated that one in 50,000 people is affected by HAE, Intellia said.The company said on Thursday that it is on track to apply for approval of Ionvo-z in the second half of 2026 and plans a U.S. launch for the therapy in the first half of 2027.Intellia dosed the first patient in the study in January 2025. The trial is designed to evaluate the efficacy and safety of lonvo-z in at least 60 adults and adolescents aged 16 years and older with Type I or Type II HAE. Key endpoints for the study include the number of HAE attacks and the number of patients who achieve attack-free status from week five through week 28.INTL stock is up &nbsp;by 38% this year, but down by about 30% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-says-ema-committee-adopted-two-positive-opinions-for-expanding-use-of-keytruda/chD3GzKR3Rp">Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details

The new price target of $30 implies an 86% upside to the stock’s closing price on Thursday. 

Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S. Food and Drug Administration. Shares of the company slumped 42% at the time of writing.The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.The company subsequently requested a meeting with the agency to push for approval of RP1. “We remain steadfastly committed to patient access while we work with the FDA to secure regulatory approval for RP1, however, without accelerated approval based on the current application, continuation of the RP1 program in advanced melanoma, including the phase 3 confirmatory trial, will not be viable,” CEO Sushil Patel said earlier this month.However, on Thursday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.replimune.com/news-releases/news-release-details/replimune-provides-update-following-type-meeting-fda">stated</a> that it had completed a meeting with the FDA on September 16 regarding the letter pertaining to the application for approval of RP1. The company stated that it is evaluating the feedback from the FDA to determine its next steps, and the path forward under the accelerated approval pathway has not yet been determined.“We remain committed to working with the FDA to determine an expeditious path forward for RP1,” Patel reiterated on Thursday.RP1 is Replimune’s lead product candidate. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:571/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_11_25_42_AM_png_83a21ea942.webp" alt="REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="571" height="64"><figcaption>REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that a strategic review announcement is due in the coming months.<stembedurl>https://stocktwits.com/Bakhmutbull2/message/629140552</stembedurl>A more optimistic user, however, said that RP1 remains “a therapy to watch” for melanoma patients.<stembedurl>https://stocktwits.com/sousayuri/message/629114614</stembedurl>REPL stock is down by about 73% this year and by about 70% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ge-healthcare-reportedly-eyes-selling-stake-in-china-unit/chDcxTmR3bI">GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Replimune Stock Plunged 42% Today – Here’s Why

The company stated that it is evaluating feedback from the FDA regarding the approval of its lead candidate for the treatment of advanced melanoma to determine its next course of action. 

Cracker Barrel Old Country Store (CBRL) shares declined 3% in early trading on Thursday after multiple Wall Street analysts trimmed their price target on the stock, noting a decline in traffic following the company’s controversial logo change in late August.Citigroup lowered the firm's price target on Cracker Barrel to $42 from $47 and maintained a ‘Sell’ rating, according to TheFly. The company reset fiscal 2026 expectations to well below estimates, acknowledging that the first quarter began in a "deep traffic hole" due to the logo mishap.Cracker Barrel reverted to its old logo in August following a week-long controversy over its new logo that drew outrage from President Donald Trump as well. Last week, the company announced that it would suspend remodeling of restaurants to retain the “Old Timer” logo.Retail sentiment on <a href="https://stocktwits.com/symbol/CBRL">Cracker Barrel</a> dipped to ‘bearish’ from ‘bullish’ territory a day ago, with chatter at ‘high’ levels, according to data from Stocktwits. The retail message count also jumped nearly 500% over 24 hours as of Thursday morning on Stocktwits.<figure class="image"><img style="aspect-ratio:802/87;" src="https://news.stocktwits-cdn.com/CBRL_sentiment_png_30976da71f.webp" alt="CBRL sentiment .png" width="802" height="87"><figcaption>CBRL sentiment and message volume September 18, 2025, as of 10 am ET | Source: Stocktwits</figcaption></figure>Piper Sandler also cut its price target on Cracker Barrel to $49 from $56 and maintained a ‘Neutral’ rating, while Bank of America lowered its price target to $42 from $48 and maintained an ‘Underperform’ rating.Bank of America noted that stronger fiscal fourth-quarter restaurant comparable growth was "overshadowed by the recent uproar" around the company's logo change and store prototype test.CFO Craig Pommells said during the post-earnings call that traffic for the first half of August was down about 1%. Since August 19, the date of the initial logo change, traffic has declined approximately 8%.Cracker Barrel said that it expects fiscal 2026 total revenue to be between $3.35 billion and $3.45 billion, compared with estimates of $3.52 billion, according to data from Fiscal AI.Truist Securities trimmed its price target on Cracker Barrel to $58 from $62 and recommended a buy based on the weakness, citing its view that the core drivers of the brand's turnaround remain intact and that sales may start to recover from the rebranding and the resumption of Fall Menu marketing.Shares of Cracker Barrel have declined by nearly 7% and fallen 20% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ondas-stock-rising-today/chDcxyCR3bO">Why Is Ondas Stock Rising Today?</a>

A Cracker Barrel sign featuring the old logo hangs on the outside of a restaurant on August 21, 2025 in Homestead, Florida. (Photo by Joe Raedle/Getty Images)

Cracker Barrel In Spotlight After Slew Of Price Target Cuts: Citi Says Q1 Began In A ‘Deep Traffic Hole’ Post Logo Change

Citigroup lowered its price target on the stock to $42 from $47, noting that the company reset fiscal 2026 expectations well below estimates, while acknowledging that the first quarter began in a "deep traffic hole" due to the logo mishap.

Krispy Kreme (DNUT) shares jumped over 6% before the bell on Thursday and witnessed a 633% increase in retail user message count on Stocktwits in the last 24 hours after FBI Director Kash Patel reportedly noted the company has a “good investment” opportunity.According to Bloomberg News, during his testimony in Congress, Patel was asked about his purchase of individual stocks while in office. The report added that Patel explained he has “long liked” to trade stocks.Patel noted that he saw “good investment” opportunities in Krispy Kreme and ON Semiconductor Corp. (ON), according to the report. “I just follow certain industries,” he said at the hearing, “and I thought they would be a good investment.”A user on Stocktwits noted that it was “crazy” that a Senate oversight meeting led to a boost in stock price for a donut company.<a href="https://stocktwits.com/Werewolfoflondon/message/629073308">https://stocktwits.com/Werewolfoflondon/message/629073308</a>Retail sentiment on <a href="https://stocktwits.com/symbol/DNUT">Krispy Kreme</a> jumped to ‘bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:795/97;" src="https://news.stocktwits-cdn.com/DNUT_sentiment_png_f84903838d.webp" alt="DNUT sentiment.png" width="795" height="97"><figcaption>DNUT sentiment and message volume September 18, 2025, as of 7 am ET | Source: Stocktwits</figcaption></figure>In July, Patel&nbsp;had&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://static.notus.org/3b/61/46d6712d4aff9412d01276fbf797/kashyap-patel-07-21-2025-278t.pdf">disclosed</a> that he had purchased between $15,000 and $50,000 worth of Krispy Kreme shares and between $50,000 and $100,000 worth of ON Semiconductor shares.Bloomberg noted that Joe Neguse of Colorado directed the question to Patel in the context of a growing bipartisan initiative aimed at prohibiting members of Congress from trading individual stocks.The report said that the proposed measure is part of a broader campaign to strengthen anti-corruption safeguards and that, notably, officials in the executive branch, such as Patel, would remain exempt from the restrictions under the current proposal.Shares of Krispy Kreme have declined 68% this year and lost 74% of its value in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nike-shares-are-rising-premarket-heres-why/chDcAX9R3Gt">Nike Shares Are Rising Premarket: Here's Why</a>

The Krispy Kreme corporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Krispy Kreme Stock Pops After FBI Director Kash Patel Reportedly Endorses It As A ‘Good Investment’: Retail Chatter Soars Over 600%

According to a Bloomberg News report, Patel noted during his testimony in Congress that he saw “good investment” opportunities in Krispy Kreme and ON Semiconductor Corp.

iShares Trust - iShares Russell 2000 BuyWrite ETF

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

IWMW
iShares Russell 2000 BuyWrite ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWMW News

IWMW iShares Russell 2000 BuyWrite ETF